Mr. Abdullah Adnan, D.O Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1201 E Michigan Ave, Jackson, MI 49201 Phone: 847-962-1386 Fax: 517-205-7525 |
Andrea Lynn Woodring, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 205 N East Ave, Jackson, MI 49201 Phone: 517-205-4704 |
Dr. Bhavna Rajesh Shah, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 205 N East Ave, Jackson, MI 49201 Phone: 517-788-4897 |
Zahirul Talukder, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 2108 4th St, Suite A, Jackson, MI 49203 Phone: 517-788-9700 Fax: 517-784-8975 |
Iman S Abou-chakra, M.D. Physical Medicine & Rehabilitation - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E Michigan Ave, Ste 300, Jackson, MI 49201 Phone: 517-841-1431 Fax: 517-841-1432 |
News Archive
One of the most intriguing questions in cancer research is what causes metastatic tumour migration, why some tumour cells manage to migrate to other parts of the body but others cells don't. International investigation conducted by Enrique Mart-n Blanco, CSIC researcher at the Institute of Biology of Barcelona, located in the Barcelona Science Park, reveals that cells make use of a natural mechanism for this.
On Kaiser Health News' blog, staff writer Julie Appleby writes: "Insurers who offer 'association health plans,' which are often sold through trade groups or other organizations of affiliated members, will face the same scrutiny of premium rate hikes as other types of insurance, federal officials said Thursday."
InVivo Therapeutics Corporation, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has signed a lease to open its first manufacturing and development facility in Medford, Massachusetts. The company expects to use this new facility to scale up the manufacturing process for its lead product candidate, a novel biocompatible polymer scaffolding device used to treat acute open-wound SCI.
Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT) today announced it has received a $2,075 million two-year grant from the U.S. Army to study the Company's proprietary Oxycyte® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).
Revance Therapeutics, Inc. today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow's feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago.
› Verified 3 days ago